Albireo Prices Public Offering of 4,000,000 Shares of Common Stock
Albireo Pharma, Inc. (Nasdaq: ALBO) has announced the pricing of an underwritten public offering of 4,000,000 shares of common stock at $40.00 each, aiming to raise approximately $160 million before fees. The offering is expected to close around September 14, 2020, pending customary conditions. The underwriters also have a 30-day option to purchase an additional 600,000 shares. Cowen and William Blair lead as joint book-running managers for the offering. This offering is in alignment with Albireo's focus on developing bile acid modulators for orphan pediatric liver diseases.
- The public offering aims to raise approximately $160 million, which may support ongoing clinical trials.
- Albireo's lead candidate, odevixibat, is in Phase 3 trials for treating rare pediatric liver diseases.
- The offering could lead to dilution of existing shares for current shareholders.
- Dependence on successful completion of the public offering amidst market uncertainties.
BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 4,000,000 shares of its common stock at a price to the public of
Cowen and William Blair are acting as the joint book-running managers and representatives of the underwriters for the offering. Wedbush PacGrow, H.C. Wainwright & Co. and Baird are acting as co-managers for the offering.
The offering is being made only by means of a written prospectus and related prospectus supplement forming part of a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission (SEC) on May 7, 2020 and declared effective by the SEC on May 18, 2020. The preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering were filed with the SEC on September 8, 2020. The final prospectus supplement and accompanying prospectus will be filed with the SEC and will be available at the SEC’s website located at www.sec.gov, copies of which may be obtained, when available, from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by telephone at (833) 297-2926, or from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by email at prospectus@williamblair.com or by telephone at 1-800-621-0687.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Albireo
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in progressive familial intrahepatic cholestasis (PFIC) and biliary atresia, with a third Phase 3 trial being planned in Alagille syndrome. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements, other than statements of historical fact, regarding, among other things, the completion and timing of the public offering and the anticipated total gross proceeds from the offering. Albireo often uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “planned,” “continue,” “guidance,” and similar expressions to identify forward-looking statements. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including, but not limited to: the completion of the public offering and other risks and uncertainties that are described under the heading “Risk Factors” in Albireo’s preliminary prospectus supplement filed with the SEC on September 8, 2020, Albireo’s most recent Annual Report on Form 10-K or in subsequent filings that it makes with the Securities and Exchange Commission. As a result of risks and uncertainties that Albireo faces, the results or events indicated by any forward-looking statement may not occur. Albireo cautions you not to place undue reliance on any forward-looking statement. In addition, any forward-looking statement in this press release represents Albireo’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Albireo disclaims any obligation to update any forward-looking statement, except as required by applicable law.
Investor Contact:
Hans Vitzthum
LifeSci Advisors, LLC
617-430-7578
Media Contact:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Claire LaCagnina, 6 Degrees, 315-765-1462, clacagnina@6degreespr.com
FAQ
What is the size and purpose of the Albireo public offering?
When is the expected closing date for Albireo's public offering?
What are the key details about Albireo's stock offering?
How might Albireo's stock offering affect current shareholders?
